Skip to content

Clinical study of 4L group lymph node dissection in lung cancer patients

Clinical study of 4L group lymph node dissection in lung cancer patients

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1900027344
Enrollment
Unknown
Registered
2019-11-09
Start date
2019-12-01
Completion date
Unknown
Last updated
2019-11-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-Small Cell Lung Cancer

Interventions

None listed

Sponsors

Shanghai Chest Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: (1) patients aged 18 years and above; (2) the lesion is located in the left lung; (3) single lesion; (4) the preoperative classification is stage I to stage IIIA of NSCLC, in which the patients with suspected positive lymph nodes needing EBUS; (5) without neoadjuvant therapy such as chemotherapy, radiotherapy, radiotherapy and chemotherapy before operation; (6) preoperative examination and evaluation should be carried out according to NCCN guidelines to make sure that the patients' cardiopulmonary function can tolerate the operation and exclude the patients with distant metastasis and serious basic diseases; (7) the lesions can be completely removed by VATS, RATS or traditional thoracotomy; (8) general status score: PS score < 3.

Exclusion criteria

Exclusion criteria: (1) small cell lung cancer or metastasis is confirmed by preoperative puncture or intraoperative freezing; (2) multiple primary lesions in the same or different lobes; (3) two or more station lymph node metastasis, N3 lymph node metastasis or distant metastasis; (4) the preoperative examination found that the cardiopulmonary function could not tolerate the operation or there were serious basic diseases, such as serious hypertension, diabetes, neurological and mental system diseases, which could not be operated; (5) the lesions could not be excised completely or palliatively; (6) those who lost the interview or voluntarily quit the study; (7) those who are generally in poor condition, unable to take care of their own life, and unable to accept surgery.

Design outcomes

Primary

MeasureTime frame
Lymph node dissection;Perioperative situation;

Secondary

MeasureTime frame
3-year Disease Free Survival;3-year Overall Survival;5-year Disease Free Survival;5-year Overall Survival;

Countries

China

Contacts

Public ContactYao Feng

Shanghai Chest Hospital

yaofeng6796678@126.com+86 13636354837

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026